ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 594

Evidence of Human Leucozyte Antigen-B27 in Healthy Individuals and Patients with Uveitis Is a Risk Factor for Alterations in Bone Metabolism

Sarah Schmidt1, Stephanie Finzel1, Jürgen Rech2, Matthias Englbrecht1, Silke Winkler1, Isabel Schmidt1, Roula Said-Nahal3, Maxime A. Breban3 and Georg A. Schett1, 1Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, 2Medizinische Klinik 3, University of Erlangen-Nuremberg, Erlangen, Germany, 3Rheumatology Division, Ambroise Paré Hospital (AP-HP), and Versailles Saint Quentin en Yvelines University, Boulogne-Billancourt, France

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: bone metabolism, human leukocyte antigens (HLA) and spondylarthropathy

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Spondylarthritis and Psoriatic Arthritis - Pathogenesis, Etiology

Session Type: Abstract Submissions (ACR)

Background/Purpose: To test whether positivity for HLA-B27 per se is associated with changes of biomarkers of the Wnt pathway.

HLA-B27 is strongly associated with the development of spondyloarthritis (SPA), a disease characterized by new bone formation and ankylosis of joints and intervertebral spaces. We have recently shown the role of the two Wnt antagonists, dickkopf 1 (DKK1) and sclerostin in new bone formation in SPA. We therefore hypothesized that HLA-B27 itself may be associated with alterations in expression of DKK1 and sclerostin.

Methods: 31 patients with HLA-B27 positive SPA, 30 patients with HLA-B27 positive uveitis as well as 30 healthy carriers of HLA-B27 were included. Furthermore, we assessed 32 HLA-B27 negative healthy controls comparable for age and gender. We evaluated total DKK1 and sclerostin levels in sera of all individuals by enzyme-linked immunosorbent assays (ELISA). Statistical analysis was done by t-tests using SPSS version 18.0.

Results: Healthy HLA-B27 positive individuals showed significant lower levels of DKK1 compared to negative controls (T (60)= -4.615, p< 0.001). Moreover, DKK1 levels were significant reduced in HLA-B27 positive SPA-patients (T (61)= -3.670, p=0.001) and in HLA-B27 positive uveitis patients (T(60)= -2.445, p=0.017). Lowest levels of DKK1 were found in HLA-B27 positive healthy carriers. Serum levels of sclerostin were significantly lower in HLA-B27 positive SPA-patients compared to HLA-B27 negative individuals (T (61)= -3.130, p=0.003). Additionally, serum levels of sclerostin were distinctly reduced in HLA-B27 positive uveitis patients and in HLA-B27 positive healthy carriers.

Conclusion: HLA-B27 positivity is associated with low levels of DKK1 and sclerostin independent from the presence of clinical symptoms of SPA. Both HLA-B27 healthy carriers as well as HLA-B27 associated uveitis without SPA show lower levels of these two Wnt antagonists than normal HLA-B27 negative controls. These data suggest that alterations in bone metabolism even occur in the absence of clinical SPA and are associated with HLA-B27 carriage.


Disclosure:

S. Schmidt,
None;

S. Finzel,
None;

J. Rech,
None;

M. Englbrecht,
None;

S. Winkler,
None;

I. Schmidt,
None;

R. Said-Nahal,
None;

M. A. Breban,
None;

G. A. Schett,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/evidence-of-human-leucozyte-antigen-b27-in-healthy-individuals-and-patients-with-uveitis-is-a-risk-factor-for-alterations-in-bone-metabolism/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology